menu
    • menu

    Company profile for Olema Oncology

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Olema OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    665 3rd St., Suite 250 San Francisco, CA 94107
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://olema.com
    Linkedin
    Linkedin
    https://www.linkedin.com/company/olema-pharmaceuticals-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Olema Oncology To Unveil OP-3136 Clinical Data At 2026 ASCO
    Olema Oncology To Unveil OP-3136 Clinical Data At 2026 ASCO

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3278398/0/en/olema-oncology-to-present-initial-clinical-data-for-op-3136-at-the-2026-asco-annual-meeting.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share
    Olema Oncology Unveils Palazestrant, OP-3136 Preclinical Data
    Olema Oncology Unveils Palazestrant, OP-3136 Preclinical Data

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187991

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    Olema Oncology Issues Inducement Grants Under Nasdaq Rule
    Olema Oncology Issues Inducement Grants Under Nasdaq Rule

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267852/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    Olema Oncology to Present Palazestrant, OP-3136 Data in 2026
    Olema Oncology to Present Palazestrant, OP-3136 Data in 2026

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257678/0/en/Olema-Oncology-to-Present-Preclinical-Data-for-Palazestrant-and-OP-3136-at-the-2026-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Olema Oncology Reveals 2025 Financial Results
    Olema Oncology Reveals 2025 Financial Results

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256109/0/en/Olema-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-and-Operating-Results.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Olema Oncology Issues Inducement Grants Under Nasdaq Rules
    Olema Oncology Issues Inducement Grants Under Nasdaq Rules

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248965/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search